CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
March 2019—EntroGen announced the availability of a lung cancer RNA panel intended for the qualitative detection of ALK, ROS1, and RET fusion genes, as well as MET exon 14 skipping mutations in human lung RNA.
The one-step reverse transcriptase PCR assay combines first-strand cDNA synthesis and subsequent amplification of mutant and reference genes, designed to minimize hands-on time and reduce the risk of introducing contaminants during preamplification. The three-step workflow produces results in less than two hours and detects 47 variants in eight reactions, the company reports.
Pages: 1 2